We collaborate with biotech firms, government agencies, and global partners to translate cutting-edge research into clinical applications. Our work focuses on developing allogeneic platforms and pioneering therapies for cancer, neurodegeneration, autoimmunity, and inflammation. By leveraging CAR T cell technology, chimeric antigen receptor therapies, and innovative treatment strategies, we aim to bring transformative solutions from the lab to clinical trials, improving outcomes for patients worldwide.